• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)的致病特征:免疫逃避的可能机制?

The Pathogenic Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Possible Mechanisms for Immune Evasion?

机构信息

State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan, China.

Key Laboratory of Preventive Veterinary Medicine of Hubei Province, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China.

出版信息

Front Immunol. 2021 Jul 14;12:693579. doi: 10.3389/fimmu.2021.693579. eCollection 2021.

DOI:10.3389/fimmu.2021.693579
PMID:34335604
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8317057/
Abstract

Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) is a newly emerging, highly transmitted and pathogenic coronavirus that has caused global public health events and economic crises. As of March 4, 2021, more than 100 million people have been infected, more than 2 million deaths have been reported worldwide, and the numbers are continuing to rise. To date, a specific drug for this lethal virus has not been developed to date, and very little is currently known about the immune evasion mechanisms of SARS-CoV-2. The aim of this review was to summarize and sort dozens of published studies on PubMed to explore the pathogenic features of SARS-CoV-2, as well as the possible immune escape mechanisms of this virus.

摘要

严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)是一种新出现的、高传播性和致病性冠状病毒,已引发全球公共卫生事件和经济危机。截至 2021 年 3 月 4 日,已有超过 1 亿人感染,全球报告超过 200 万人死亡,且数字还在继续上升。迄今为止,尚未针对这种致命病毒开发出特定药物,目前对 SARS-CoV-2 的免疫逃逸机制知之甚少。本综述的目的是总结和整理几十篇发表在 PubMed 上的研究,以探讨 SARS-CoV-2 的发病特征,以及该病毒可能的免疫逃逸机制。

相似文献

1
The Pathogenic Features of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Possible Mechanisms for Immune Evasion?严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)的致病特征:免疫逃避的可能机制?
Front Immunol. 2021 Jul 14;12:693579. doi: 10.3389/fimmu.2021.693579. eCollection 2021.
2
SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response.SARS-CoV-2:致病机制与宿主免疫应答。
Adv Exp Med Biol. 2021;1313:99-134. doi: 10.1007/978-3-030-67452-6_6.
3
Coronavirus disease 2019 and asthma, allergic rhinitis: molecular mechanisms and host-environmental interactions.新型冠状病毒病 2019 与哮喘、变应性鼻炎:分子机制与宿主-环境相互作用。
Curr Opin Allergy Clin Immunol. 2021 Feb 1;21(1):1-7. doi: 10.1097/ACI.0000000000000699.
4
Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV.SARS-CoV-2 的先天免疫逃避:与 SARS-CoV 的比较。
Rev Med Virol. 2020 Nov;30(6):1-9. doi: 10.1002/rmv.2135. Epub 2020 Jul 30.
5
COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2.COVID-19 大流行:对 SARS-CoV-2 结构、功能和 hACE2 受体识别的深入了解。
PLoS Pathog. 2020 Aug 21;16(8):e1008762. doi: 10.1371/journal.ppat.1008762. eCollection 2020 Aug.
6
Children and COVID-19: Microbiological and immunological insights.儿童与 COVID-19:微生物学和免疫学新视角。
Pediatr Pulmonol. 2020 Oct;55(10):2547-2555. doi: 10.1002/ppul.24978. Epub 2020 Jul 30.
7
Immune evasion of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); molecular approaches.严重急性呼吸综合征冠状病毒 2 型(SARS-CoV-2)的免疫逃逸;分子方法。
Mol Immunol. 2023 Apr;156:10-19. doi: 10.1016/j.molimm.2022.11.020. Epub 2022 Nov 24.
8
SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion.SARS-CoV-2 非结构蛋白及其在宿主免疫逃逸中的作用。
Viruses. 2022 Sep 8;14(9):1991. doi: 10.3390/v14091991.
9
Molecular Insights into Severe Acute Respiratory Syndrome Coronavirus 2 Pathobiology: Dissecting the Interplay between Cellular Innate Immunity and Immune Evasion.深入了解严重急性呼吸综合征冠状病毒 2 发病机制的分子机制:剖析细胞固有免疫与免疫逃避之间的相互作用。
Crit Rev Immunol. 2020;40(6):485-496. doi: 10.1615/CritRevImmunol.2020035855.
10
Pathogenesis-directed therapy of 2019 novel coronavirus disease.针对 2019 新型冠状病毒病的发病机制导向治疗。
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.

引用本文的文献

1
Possible therapeutic targets for SARS-CoV-2 infection and COVID-19.新型冠状病毒(SARS-CoV-2)感染及新冠肺炎(COVID-19)可能的治疗靶点。
J Allergy Infect Dis. 2021;2(3):75-83. doi: 10.46439/allergy.2.028.
2
Irisin, Exercise, and COVID-19.鸢尾素、运动与 COVID-19
Front Endocrinol (Lausanne). 2022 Jun 17;13:879066. doi: 10.3389/fendo.2022.879066. eCollection 2022.
3
COVID-19: Are We Facing Secondary Pellagra Which Cannot Simply Be Cured by Vitamin B3?新型冠状病毒肺炎:我们是否面临不能仅用维生素 B3 治愈的继发性糙皮病?

本文引用的文献

1
An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies.新冠病毒刺突蛋白上一个被抗体靶向的增强感染性位点。
Cell. 2021 Jun 24;184(13):3452-3466.e18. doi: 10.1016/j.cell.2021.05.032. Epub 2021 May 24.
2
The ORF8 protein of SARS-CoV-2 mediates immune evasion through down-regulating MHC-Ι.SARS-CoV-2 的 ORF8 蛋白通过下调 MHC-Ι 实现免疫逃逸。
Proc Natl Acad Sci U S A. 2021 Jun 8;118(23). doi: 10.1073/pnas.2024202118.
3
Type-I interferon signatures in SARS-CoV-2 infected Huh7 cells.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染的Huh7细胞中的I型干扰素特征
Int J Mol Sci. 2022 Apr 13;23(8):4309. doi: 10.3390/ijms23084309.
Cell Death Discov. 2021 May 18;7(1):114. doi: 10.1038/s41420-021-00487-z.
4
Systematic functional analysis of SARS-CoV-2 proteins uncovers viral innate immune antagonists and remaining vulnerabilities.系统功能分析 SARS-CoV-2 蛋白揭示了病毒先天免疫拮抗剂和剩余弱点。
Cell Rep. 2021 May 18;35(7):109126. doi: 10.1016/j.celrep.2021.109126. Epub 2021 Apr 27.
5
SARS-CoV-2 promote autophagy to suppress type I interferon response.严重急性呼吸综合征冠状病毒2促进自噬以抑制I型干扰素反应。
Signal Transduct Target Ther. 2021 May 8;6(1):180. doi: 10.1038/s41392-021-00574-8.
6
SARS-CoV-2 Nucleocapsid Protein Targets RIG-I-Like Receptor Pathways to Inhibit the Induction of Interferon Response.SARS-CoV-2 核衣壳蛋白靶向 RIG-I 样受体途径抑制干扰素反应的诱导。
Cells. 2021 Mar 2;10(3):530. doi: 10.3390/cells10030530.
7
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.SARS-CoV-2 B.1.1.7 对 mRNA 疫苗诱导抗体的敏感性。
Nature. 2021 May;593(7857):136-141. doi: 10.1038/s41586-021-03412-7. Epub 2021 Mar 11.
8
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.SARS-CoV-2 变异株 B.1.1.7 易被原始刺突疫苗诱导产生的中和抗体中和。
Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3. doi: 10.1016/j.chom.2021.03.002. Epub 2021 Mar 5.
9
Detection of a SARS-CoV-2 variant of concern in South Africa.南非出现一种令人关注的 SARS-CoV-2 变异株。
Nature. 2021 Apr;592(7854):438-443. doi: 10.1038/s41586-021-03402-9. Epub 2021 Mar 9.
10
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.SARS-CoV-2 变体 B.1.351 和 B.1.1.7 的抗体抗性。
Nature. 2021 May;593(7857):130-135. doi: 10.1038/s41586-021-03398-2. Epub 2021 Mar 8.